Pfizer Opens New $743-M API Mfg Facility
Pfizer has opened a new SGD$1 billion (US$743 million) active pharmaceutical ingredient (API) manufacturing facility to expand its site in Tuas Biomedical Park, Singapore.
The facility spans 429,000 square feet and will produce various small-molecule APIs for Pfizer’s oncology, pain, and antibiotic medicines to markets globally. The facility has passed all necessary final performance qualification checks and has begun commercial manufacturing of products.
The construction of the facility began in 2020. In addition to the existing buildings, the facility has the capacity to add processing suites, dry-end suites, dispensaries, warehouse, and ancillary equipment.
